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OBJECTIVE—Vascular adhesion protein-1 (VAP-1) participates
in inﬂammation and catalyzes the breakdown of amines to
produce aldehyde, hydrogen peroxide, and ammonia. Serum
VAP-1 correlates positively with both acute hyperglycemia and
diabetes. We conducted a cohort study to evaluate whether
serum VAP-1 predicts 10-year survival in type 2 diabetic patients.
RESEARCH DESIGN AND METHODS—Between July 1996
and June 2003, we enrolled 661 type 2 diabetic subjects at
National Taiwan University Hospital. Serum VAP-1 in the samples
obtained at enrollment was measured by time-resolved immuno-
ﬂuorometric assay. The vital status of all subjects was ascer-
tained by linking their data with computerized death certiﬁcates
in Taiwan.
RESULTS—The medium follow-up period was 10.4 years.
Subjects with serum VAP-1 in the highest tertile had a hazard
ratio (HR) of 2.19 (95% CI 1.17–4.11) for all-cause mortality ad-
justed for age, sex, smoking, history of cardiovascular disease,
obesity, hypertension, hemoglobin A1c, diabetes duration, total
cholesterol, use of statins, abnormal ankle-brachial index, esti-
mated glomerular ﬁltration rate (eGFR), and proteinuria. The
adjusted HRs for logarithmically transformed serum VAP-1 were
5.83 (95% CI 1.17–28.97) for cardiovascular mortality, 6.32
(95% CI 1.25–32.00) for mortality from cardiovascular and diabetic
causes, and 17.24 (95% CI 4.57–65.07) for cancer mortality. There
were four variables, including age, serum VAP-1, proteinuria, and
eGFR, which could enhance mortality prediction signiﬁcantly.
CONCLUSIONS—Serum VAP-1 can predict 10-year all-cause
mortality, cardiovascular mortality, and cancer mortality inde-
pendently in type 2 diabetic subjects. Serum VAP-1 is a novel
biomarker that improves risk prediction over and above estab-
lished risk factors. Diabetes 60:993–999, 2011
V
ascular adhesion protein-1 (VAP-1), discovered
by Salmi and Jalkanen (1), is a dual-function
protein. Endothelial VAP-1 can act as an adhesion
molecule (2) and is involved in leukocyte rolling,
adhesion, and transmigration, which are central steps
during leukocyte extravasation to sites of inﬂammation,
such as atherosclerotic lesions (3). Another function of
VAP-1 is as an enzyme, semicarbazide-sensitive amine
oxidase (SSAO). SSAO can catalyze the breakdown of
primary amines to produce aldehyde, hydrogen peroxide,
and ammonia (4). Hydrogen peroxide is a source of oxi-
dative stress and can contribute to the development of
atherosclerotic lesions. Along with aldehyde and glucose,
hydrogen peroxide can modify various proteins to gener-
ate advanced glycated end products (AGEs), another im-
portant factor in the development of atherosclerosis (3).
Therefore, as an adhesion molecule and an enzyme, SSAO/
VAP-1 can participate in the development of atheroscle-
rosis. Indeed, mice overexpressing VAP-1 in the endothe-
lium have shown increased concentrations of serum AGEs,
enhanced leukocyte binding, upregulation of hepatic redox-
sensitive proteins, and accelerated atherosclerosis (5).
VAP-1 has a circulating form, which retains its enzy-
matic function. Although there are two other proteins with
SSAO activity, circulating VAP-1, the product of the AOC3
gene, has been shown to be the main source of SSAO
in human serum (6). Serum VAP-1 originates from many
tissues. In tissue-speciﬁc transgenic mice models, mice
overexpressing human VAP-1 in the endothelium, adipo-
cyte, and smooth muscle have human VAP-1 in serum
(7,8), suggesting that these tissues are the sources of se-
rum VAP-1. In addition, in ﬁve subjects with hepatic dis-
eases, the concentration of VAP-1 in the hepatic blood was
shown to be slightly higher than that in the portal blood,
suggesting that the liver may be another source of serum
VAP-1 (9), at least in subjects with hepatic diseases. Cell
culture studies have shown that human adipose tissue
explants and 3T3-L1 adipocytes can secrete VAP-1 into the
culture medium, which is inhibited by treatment with
a metalloprotease inhibitor (10,11). These experiments
suggested that, at least in part, serum VAP-1 comes from
the shedding of VAP-1 from the surface of adipocytes
through the effect of a metalloprotease. However, the way
in which serum VAP-1 is cleared from circulation remains
unknown. We have reported that subjects with chronic
kidney disease have higher serum VAP-1 (12), suggesting
a possibility that serum VAP-1 may be excreted by the
kidneys.
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ORIGINAL ARTICLERecently, we have shown that serum VAP-1 is elevated
in acute and chronic hyperglycemia and in patients with
diabetes (13). We also found that serum VAP-1 is associ-
ated positively with albuminuria and is elevated in subjects
with chronic kidney disease (12); both are risk factors for
atherosclerosis. We have also noted that the change in
serum VAP-1 after glucose challenge was correlated with
systemic oxidative stress, AGEs, and carotid intima-medial
thickness, which is an index for atherosclerosis (14). Our
results indicated that serum VAP-1 may be a good pre-
dictor for cardiovascular mortality. Therefore, we ex-
plored this issue in subjects with type 2 diabetes in this
prospective cohort study.
RESEARCH DESIGN AND METHODS
Subjects. We performed a prospective cohort study (15). Between July 1996
and June 2003, subjects with type 2 diabetes who were regularly followed up
at outpatient clinics at the Division of Endocrinology and Metabolism, Na-
tional Taiwan University Hospital, Taipei, Taiwan, were invited consecutively
to participate in the study. Written informed consent was obtained from each
subject, and the study protocol was reviewed and approved by the in-
stitutional review board.
Each subject was interviewed and underwent a physical examination by
physicians. The history of cardiovascular disease was conﬁrmed from the
admission records. Venous blood sampling was performed after overnight
fasting for the determination of plasma glucose, hemoglobin A1c, serum total
cholesterol, triglyceride, and creatinine by using an automatic analyzer
(Toshiba TBA 120FR, Toshiba Medical Systems, Tokyo, Japan). The estimated
glomerular ﬁltration rate (GFR) was calculated with the MDRD formula (16).
Serum samples were stored at 280°C in a refrigerator before the measurement
of VAP-1. Spot urine samples were collected to determine the presence of
proteinuria by performing reﬂectance colorimetry (Arkray AX4280, Kyoto,
Japan). The ankle-brachial index (ABI) was measured as the ratio of the systolic
blood pressure of the posterior tibial artery or dorsalis pedis and the brachial
artery. An ABI greater than 1.3 or less than 0.9 was deﬁned as abnormal (17).
Patients were followed up until 31 December 2008. Vital status, date of
death, and cause of death of all subjects were obtained from the computerized
death certiﬁcates maintained by the Department of Health, Executive Yuan in
Taiwan (18). Cause of death was deﬁned by the ICD9 (cardiovascular death,
390–459 and 785; diabetes, 250; malignancy, 140–239 and 288).
Measurement of serum VAP-1. Serum VAP-1 and its SSAO activity are quite
stable. When stored properly at 270°C, it has been shown to remain intact
after two years (19). Serum VAP-1 was measured by time-resolved immuno-
ﬂuorometric assay as stated previously (12–14). Brieﬂy, the assay used a biotin-
conjugated monoclonal anti-human VAP-1 antibody (Biotie Therapies, Finland)
as a capturer on a streptavidin-coated microtiter plate. Detection of bound se-
rum VAP-1 was performed using a different europium-conjugated anti-human
VAP-1 antibody (Biotie Therapies). The time-resolved ﬂuorescence was mea-
sured using a ﬂuorometer (Victor
2 Multilabel Counter, PerkinElmer Finland Oy)
at 615 nm. Serum VAP-1 concentration was quantiﬁed on the basis of a refer-
ence sample of highly puriﬁed human serum VAP-1 (Biovian). The R
2 of the
standard curves was 0.997–1.000. The intraassay coefﬁcients of variation were
3.7, 5.2, and 8.9% for quality control samples with concentrations 1,000, 500, and
100 ng/mL, respectively. The interbatch coefﬁcients of variation from quality
control samples were 4.4–10.2%.
Statistical analysis. Categorical variables were reported as the percentage of
patients in the subgroup. The distributions of continuous variables were ex-
amined by the Shapiro-Wilk test. Continuous variables distributed normally
were presented as means and SD. Continuous variables with skewed distri-
bution were analyzed after logarithmic transformation and were presented as
medians (interquartile ranges). The Student t tests, x
2 tests, and ANOVA were
used to identify the differences in clinical characteristics between survivors
and nonsurvivors and among subgroups by serum VAP-1 tertile. Survival in
subgroups was estimated by the Kaplan-Meier method and was tested by log-
rank test. Multivariate Cox proportional hazards models were applied to es-
timate the hazard ratios (HRs) of predictors for all-cause and disease-speciﬁc
mortality. Variables signiﬁcantly associated with survival time in univariate
Cox proportional hazards models and clinically important variables were in-
cluded in multivariate analyses. Because only 418 subjects (63.2%) had data on
serum creatinine, estimated GFR was added last to the statistical models. A
proportional hazards assumption was evaluated by log-log plots, observed
versus expected plots, and was tested for goodness of ﬁt based on Schoenfeld
residuals and scaled Schoenfeld residuals. The concordance statistics, which
are similar to the area under the receiver-operating characteristic (ROC)
curve, and area under the ROC curve, were used to assess the ability of the
statistical model to predict the mortality or survival of the patients during the
10-year follow-up. They ranged from 0.5 (no predictive ability) to 1 (perfect
predictive ability). A two-tailed P value below 0.05 was considered signiﬁcant.
Stata/SE 9.0 for Windows (StataCorp LP, TX) was used for statistical analyses.
RESULTS
We included 661 subjects with type 2 diabetes (327 men and
334 women), with mean age 61.9 6 9.8 years and a medium
follow-up period of 10.4 (interquartile range, 7.0–11.4)
years. The correlation coefﬁcients between serum VAP-1
and fasting plasma glucose, postprandial plasma glu-
cose, and HbA1c were 0.20, 0.27, and 0.32, respectively
(all P , 0.0001).
During follow-up, 160 subjects died, including 59 (36.9%)
from malignancy, 30 (18.8%) from diabetes, 27 (16.9%)
from cardiovascular diseases, 12 (7.5%) from kidney dis-
eases, nine (5.6%) from infectious diseases, eight (5.0%)
from gastrointestinal or liver diseases, ﬁve (3.1%) from
traumatic injuries, and others. At baseline, these subjects
were older, had longer duration of diabetes, higher HbA1c,
and lower estimated GFR (Table 1). A higher percentage of
these subjects had a smoking habit, history of cardiovas-
cular disease, hypertension, proteinuria, and abnormal
ABI. Their serum VAP-1 levels were higher, and more
subjects had serum VAP-1 in the highest tertile.
People with serum VAP-1 in the highest tertile were
older, had higher mortality, longer duration of diabetes,
higher fasting plasma glucose, higher postprandial plasma
glucose, higher HbA1c, and lower estimated GFR (Table 2).
There was a higher percentage of women and subjects
with proteinuria and fewer smokers in this tertile.
Kaplan-Meier survival curves showed that during 10.4
years of follow-up, subjects with serum VAP-1 in the
highest tertile had a lower rate of survival than subjects in
the other tertiles (Fig. 1). In Table 3, the HRs of all-cause
mortality are shown to be signiﬁcantly higher in subjects
with serum VAP-1 in the highest tertile, after adjusting for
age, sex, smoking, history of cardiovascular disease, BMI
category, hypertension, HbA1c, diabetes duration, total
cholesterol, use of statins, abnormal ABI, estimated GFR,
and/or proteinuria in different models. Serum VAP-1 sig-
niﬁcantly predicted all-cause mortality in different sub-
groups divided by age (at 65 years), sex, smoking status,
history of cardiovascular disease, BMI category (at 24 and
27 kg/m
2), hypertension, HbA1c (at 7.4%), diabetes duration
(at 9 years), plasma total cholesterol (at 200 mg/dL), use of
statins, ABI category, estimated GFR (at 77 mL/min per
1.73 m
2), and proteinuria, adjusted for age, sex, smoking,
history of cardiovascular disease, BMI category, hyper-
tension, HbA1c, diabetes duration, total cholesterol, sta-
tins, and ABI, apart from the stratiﬁcation variable. Further
adjustment for estimated GFR and proteinuria showed
similar results, except in overweight subjects, those with-
out hypertension, and in subjects with plasma total cho-
lesterol greater than 200 mg/dL (all P = 0.05–0.10).
The results of disease-speciﬁc mortality are shown in
Table 4. Serum VAP-1 predicted 10-year cardiovascular
mortality independent of age, sex, smoking, and history of
cardiovascular disease. There were 30 subjects whose
underlying cause of death was diabetes. According to the
rules deﬁned by the World Health Organization (20), di-
abetes is likely to be selected as the underlying cause of
death in subjects who die directly from cardiovascular dis-
eases. Therefore, we analyzed predictors for cardiovascular
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serum VAP-1 signiﬁcantly predicted cardiovascular and
diabetes-related mortality adjusted for history of cardio-
vascular disease, age, sex, smoking, BMI category, hyper-
tension, HbA1c, diabetes duration, total cholesterol, use
of statins, and/or estimated GFR. Fifty-nine subjects died
of cancer, including colon cancer (n = 26), hepatobiliary
cancer (n = 13), lymphoma or leukemia (n = 5), lung cancer
(n = 4), urinary tract cancer (n = 4), and others (n =7 ) .O f
interest, serum VAP-1 predicted cancer-related mortality
independently (model 4). More speciﬁcally, serum VAP-1
independently predicted colon cancer-related mortality (HR
12.19 for logarithmically transformed serum VAP-1, 95% CI
2.37–62.7, P = 0.003, adjusted for age, sex, smoking, and
BMI category).
One might argue that the predictors may not explain
early mortality well, especially cancer mortality. There-
fore, we analyzed the results after excluding subjects who
died within the ﬁrst three years of follow-up. Serum VAP-1,
as well, can predict all-cause mortality (HR of highest
serum VAP-1 tertile 2.33, 95% CI 1.13–4.81, P , 0.05),
diabetes-related (HR of ln serum VAP-1 10.96, 95% CI 1.77–
67.97, P , 0.05), cardiovascular- and diabetes-related (HR
of ln serum VAP-1 10.88, 95% CI 1.77–67.04, P , 0.05),
and cancer mortality (HR of ln serum VAP-1 13.51, 95% CI
2.79–65.38, P , 0.01) in adjusted models. However, serum
VAP-1 did not signiﬁcantly predict cardiovascular mortality
(HR of ln serum VAP-1 3.62, 95% CI 0.64–20.43, P . 0.05),
which may reﬂect the small number of cardiovascular
mortality.
Table 5 shows the incremental predictive ability of dif-
ferent variables for all-cause mortality. Using serum VAP-1
alone can distinguish 63% of all pairs of subjects (one died
and one survived), with an area under the ROC curve
(AUC) of 0.64. In model 1, the increment in concordance
statistics and AUC were 0.11 and 0.12 for serum VAP-1 and
0.01 and 0.01 for history of cardiovascular disease, re-
spectively. In model 2, only serum VAP-1, age, and smok-
ing increased the concordance statistics, whereas serum
VAP-1, age, smoking, BMI category, hypertension, HbA1c,
diabetes duration, total cholesterol, use of statins, and ab-
normal ABI increased the AUC. In model 3, only four vari-
ables increased the concordance statistics, including serum
VAP-1, age, estimated GFR, and proteinuria. Smoking in-
creased the AUC in model 3.
DISCUSSION
In this study, we found that serum VAP-1 can indepen-
dently predict 10-year all-cause mortality, cardiovascular
mortality, and cancer-related mortality in subjects with
type 2 diabetes and in most subgroups. The improved
predictive ability of serum VAP-1 was comparable with
that of age, smoking, serum creatinine, and proteinuria.
Recently, inﬂammation has been found to be an impor-
tant cause of atherosclerosis (3). Circulating leukocytes,
especially monocytes, are recruited to blood vessels,
where they transmigrate and are activated. Various che-
mokines, cytokines, and enzymes are secreted, which may
modify low-density lipoprotein, propagate inﬂammation,
and result in atherosclerosis. Endothelial VAP-1 can partic-
ipate in inﬂammation by binding granulocytes, lymphocytes,
and monocytes, with the aid of SSAO activity (2). In sub-
jects with acute myocardial infarction, VAP-1 can mediate
TABLE 1
Baseline characteristics of survivors and nonsurvivors with type 2 diabetes
At follow-up
P Alive Dead
N (%) 501 (75.8) 160 (24.2)
Age (years) 60.2 6 9.3 67.4 6 9.1 ,0.0001
Men (%) 246 (49.1) 81 (50.6) 0.7
Smoking (%) 79 (15.8) 34 (21.3) 0.022
History of cardiovascular disease (%) 50 (10.0) 26 (16.3) 0.03
SBP (mmHg) 134 6 16 137 6 18 0.065
DBP (mmHg) 79 6 97 9 6 10 0.6
Hypertension drugs (%) 152 (30.3) 70 (43.8) 0.002
Hypertension (%) 285 (56.9) 113 (70.6) 0.002
Duration of diabetes (years) 7.0 (3.0–14.0) 12.0 (7.0–18.0) ,0.0001
Fasting plasma glucose, mmol/L (mg/dL) 8.27 6 2.55 (149 6 46) 8.44 6 2.55 (152 6 46) 0.6
Postprandial plasma glucose, mmol/L (mg/dL) 11.82 6 4.11 (213 6 74) 12.71 6 4.39 (229 6 79) 0.054
HbA1c (%) 7.6 6 1.4 7.9 6 1.5 0.036
Total cholesterol, mmol/L (mg/dL) 5.20 6 0.96 (201 6 37) 5.22 6 1.22 (202 6 47) 0.7
Statins (%) 19 (3.8) 6 (3.8) 1.0
Triglyceride, mmol/L (mg/dL) 1.52 (1.06–2.17) 135 (94–192) 1.51 (1.10–2.34) 134 (97–207) 0.2
BMI (kg/m
2) 24.65 6 3.27 24.54 6 3.25 0.7
24–47 (%) 165 (32.9) 44 (27.5) 0.3
$27 (%) 102 (20.4) 41 (25.6)
Creatinine, mmol/L (mg/dL) 80 (71–88) 0.9 (0.8–1.0) 97 (71–123) 1.1 (0.8–1.4) ,0.0001
Estimated GFR (mL/min per 1.73 m
2) 81 (22) 63 (24) ,0.0001
Proteinuria (%) 50 (10.0) 61 (38.1) ,0.001
ABI ,0.9 or .1.3 (%) 29 (5.8) 24 (15) ,0.001
Serum VAP-1 (ng/mL) 681 (581–799) 786 (636–967) ,0.0001
By tertile ,0.001
Middle, 630–780 (%) 176 (35.1) 39 (24.3)
Highest, $ 780 (%) 140 (27.9) 82 (51.2)
Means 6 SD or medians (interquartile ranges) are shown. DBP, diastolic blood pressure; SBP, systolic blood pressure.
H.-Y. LI AND ASSOCIATES
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Because serum VAP-1 originates from various tissues, it
may serve as a measure of systemic inﬂammation. On the
other hand, serum VAP-1 retains its SSAO activity (6).
End products of SSAO can modify various proteins and
generate AGEs (4). Moreover, end products of SSAO can
also propagate inﬂammation by upregulating the expres-
sion and facilitating the release of selectins in endothelium
(22). Both functions of SSAO end products contribute to
the development of atherosclerosis. Therefore, because
TABLE 2
Baseline characteristics by serum VAP-1 tertile in people with type 2 diabetes
Serum VAP-1 tertile (ng/mL) ,630 630–780 $780 P
N 224 215 222
Survivors (%) 185 (82.3) 176 (81.9) 140 (63.1)*† ,0.001
Age (years) 60.1 6 9.6 61.8 6 9.5 63.7 6 9.9*† 0.0005
Men (%) 132 (58.9) 102 (47.4)* 93 (41.9)* 0.001
Smoking (%) 48 (21.4) 35 (16.3) 30 (13.5)* 0.079
History of cardiovascular disease (%) 31 (13.8) 18 (8.4) 27 (12.2) 0.2
SBP (mmHg) 134 6 16 134 6 14 135 6 19 0.9
DBP (mmHg) 79 6 97 8 6 97 9 6 9 0.6
Hypertension drugs (%) 68 (30.4) 74 (34.4) 80 (36.0) 0.4
Hypertension (%) 133 (59.4) 130 (60.5) 135 (60.8) 0.9
Duration of diabetes (years) 5.0 (2.0–12.0) 9.0 (4.0–13.0)* 11.0 (6.0–18.0)*† ,0.0001
Fasting plasma glucose
(mmol/L, mg/dL) 7.71 6 2.00 (139 6 36) 8.27 6 2.39* (149 6 43) 8.99 6 3.05*† (162 6 55) ,0.0001
Postprandial plasma
glucose (mmol/L, mg/dL) 11.21 6 3.55 (202 6 64) 11.60 6 3.50 (209 6 63) 13.32 6 5.00*† (240 6 90) ,0.0001
HbA1c (%) 7.1 6 1.2 7.8 6 1.3* 8.2 6 1.6*† ,0.0001
Total cholesterol (mmol/L, mg/dL) 5.09 6 1.01 (197 6 39) 5.30 6 0.98 (205 6 38) 5.22 6 1.11 (202 6 43) 0.14
Statins (%) 4 (1.8) 13 (6.0) 8 (3.6) 0.065
Triglyceride (mmol/L, mg/dL) 1.52 (1.13–2.25)
134.5 (100–199.5)
1.63 (1.16–2.22)
144 (103–197)
1.45 (0.99–2.11)
128 (88–187)
0.4
BMI (kg/m
2) 24.65 6 3.00 24.79 6 3.22 24.43 6 3.55 0.5
24–47 (%) 74 (33.0) 71 (33.3) 64 (28.8) 0.6
$27 (%) 42 (18.8) 51 (23.7) 50 (22.5)
Creatinine (mmol/L, mg/dL) 80 (71–97) 0.9 (0.8–1.1) 80 (71–88) 0.9 (0.8–1.0) 80 (71–115)*† 0.9 (0.8–1.3) 0.005
Estimated GFR (mL/min per 1.73 m
2) 82 (23) 79 (22) 71 (25)*† 0.0001
Proteinuria (%) 23 (10.6) 26 (12.4) 62 (28.2)*† ,0.001
ABI ,0.9 or .1.3 (%) 14 (6.3) 17 (7.9) 22 (9.9) 0.4
Means 6 SD or medians (interquartile ranges) are shown. *P , 0.05 vs. ﬁrst tertile (serum VAP-1 , 630 ng/mL); †P , 0.05 vs. second tertile
(serum VAP-1 630–780 ng/mL).
FIG. 1. Kaplan-Meier survival curves by tertile of serum VAP-1 levels. P = 0.0001 among subgroups by tertile. Blue line, subjects with serum VAP-1
in the ﬁrst tertile; green line, subjects with serum VAP-1 in the second tertile; red line, subjects with serum VAP-1 in the third tertile.
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ﬂammation and a source of SSAO end products, it may be
a good biomarker for cardiovascular diseases. Indeed, in
this report, we found that serum VAP-1 can predict 10-year
cardiovascular mortality in subjects with type 2 diabetes
independent of the established cardiovascular risk factors.
In support of our ﬁndings, plasma SSAO has been reported
to predict all-cause mortality in subjects with chronic heart
failure, with most subjects (134/195, 68.7%) dying from
cardiovascular diseases or sudden death (23).
Subjects with diabetes are associated with an increased
risk of the development of and mortality associated with
various cancers, including colorectal cancer (24), hepato-
cellular carcinoma (25), and others. Hyperinsulinemia, in-
creased bioavailability of insulin-like growth factors-1, and
hypoadiponectinemia may be part of the causes of onco-
genesis and tumor progression in patients with diabetes
(26,27). Surprisingly, we found that serum VAP-1 predicted
cancer-related mortality in subjects with type 2 diabetes.
Because serum VAP-1 was higher in subjects with diabe-
tes (13), VAP-1/SSAO may serve as a link between diabetes
and cancer. Studies in a knock-out mice model indicated
that VAP-1 may play a role in angiogenesis, recruitment of
myeloid cells, and the growth of melanoma and lymphoma
TABLE 3
HRs (95% CI) of 10-year all-cause mortality in people with type 2 diabetes
Model
1234
VAP-1 tertile (ng/mL)
,630 1.00 1.00 1.00 1.00
630–780 0.96 (0.61–1.52) 0.86 (0.54–1.38) 0.87 (0.54–1.39) 0.89 (0.45–1.77)
$780 2.03* (1.37–3.02) 1.94† (1.25–3.00) 2.00† (1.29–3.09) 2.19‡ (1.17–4.11)
P for trend ,0.001 0.003 0.002 0.008
Age (years) 1.07* (1.05–1.09) 1.07* (1.05–1.09) 1.07* (1.05–1.09) 1.06* (1.03–1.09)
Female sex 0.93 (0.67–1.30) 0.91 (0.64–1.28) 0.91 (0.64–1.28) 0.93 (0.59–1.48)
Smoking 1.89† (1.26–2.85) 1.95† (1.29–2.95) 1.88† (1.24–2.85) 2.25† (1.34–3.79)
History of cardiovascular disease 1.49 (0.95–2.31) 1.48 (0.95–2.30) 1.30 (0.76–2.23)
BMI (kg/m
2)
,24 1.00 1.00 1.00
24–27 0.86 (0.59–1.26) 0.86 (0.59–1.26) 0.60 (0.36–1.02)
$27 1.35 (0.90–2.01) 1.35 (0.90–2.01) 0.95 (0.56–1.60)
P for trend 0.2 0.2 0.5
Hypertension 1.33 (0.94–1.90) 1.30 (0.91–1.85) 1.16 (0.72–1.87)
HbA1c (%) 1.09 (0.97–1.22) 1.08 (0.96–1.21) 1.12 (0.97–1.29)
Diabetes duration (years) 1.00 (0.98–1.02) 1.00 (0.98–1.02) 0.99 (0.96–1.01)
Total cholesterol (mg/dL) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (0.99–1.01)
Statins 0.88 (0.38–2.04) 0.82 (0.35–1.91) 0.71 (0.28–1.84)
ABI ,0.9 or .1.3 1.46 (0.91–2.32) 1.01 (0.55–1.85)
Estimated GFR (mL/min per 1.73 m
2) 0.99§ (0.98–1.00)
Proteinuria 2.38† (1.44–3.92)
*P , 0.001; †P , 0.01; ‡P , 0.05; §P = 0.060.
TABLE 4
HRs (95% CI) of 10-year disease-speciﬁc mortality in people with type 2 diabetes
Cardiovascular Diabetes Cardiovascular 1 diabetes Cancer
Ln VAP-1 (ng/mL) 5.83‡ (1.17–28.97) 9.71† (2.02–46.67) 6.32‡ (1.25–32.00) 17.24* (4.57–65.07)
History of cardiovascular disease 1.43 (0.49–4.21) 1.64 (0.61–4.40) 1.97 (0.80–4.86)
Age (years) 1.09* (1.04–1.14) 1.11* (1.06–1.16) 1.11* (1.06–1.16) 1.04‡ (1.00–1.08)
Female sex 1.34 (0.59–3.05) 0.81 (0.37–1.80) 0.90 (0.41–1.97) 0.81 (0.41–1.61)
Smoking 1.14 (0.32–4.02) 3.92† (1.62–9.50) 4.05† (1.74–9.45) 2.41‡ (1.05–5.55)
BMI (kg/m
2)
,24 1.00 1.00 1.00
24–27 1.00 (0.41–2.42) 0.72 (0.31–1.69) 0.88 (0.39–1.95)
$27 2.48‡ (1.00–6.13) 1.71 (0.67–4.31) 1.23 (0.56–2.71)
P for trend 0.088 0.5 0.7
Hypertension 0.78 (0.38–1.60)
HbA1c (%) 1.31‡ (1.06–1.64)
Diabetes duration (years) 0.99 (0.95–1.03)
Total cholesterol (mg/dL) 1.00 (0.99–1.01)
Statins 0.93 (0.20–4.32)
Estimated GFR (mL/min per 1.73 m
2) 1.00 (0.98–1.02) 0.98‡ (0.97–0.997)
Cause of death: cardiovascular (27 [16.9% of total death]), diabetes (30 [18.8%]), cardiovascular + diabetes (57 [35.6%]), and cancer
(59 [36.9%]). *P , 0.001; †P , 0.01; ‡P , 0.05.
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higher serum VAP-1 than healthy subjects (29). Serum
SSAO activity has been correlated with the angiogenic
vascular endothelial growth factor in subjects with lung
cancer (30). Serum SSAO activity has also been shown to
be higher in prostate cancer subjects with bone metastases
than subjects without metastases (31). Taken together,
these data strongly support our observations and suggest
a role for VAP-1/SSAO in cancer growth and metastasis.
However, VAP-1 may participate in tumor surveillance.
VAP-1 has been shown to mediate the adhesion of tumor-
inﬁltrating lymphocytes to head and neck squamous cell
carcinoma and hepatocellular carcinoma and to kill cancer
cells (32,33). Subjects with advanced colorectal cancer
have been shown to have low serum VAP-1 (29). In human
melanoma, a higher expression of VAP-1 in intratumoral
microvessels was associated with better ﬁve-year survival,
although there was only borderline statistical signiﬁcance
and the results were not adjusted for other confounders,
such as the presence of metastasis or not (34). To sum up,
although VAP-1/SSAO may have opposing roles in cancer
development and progression, our results favored the hy-
pothesis that there was a positive effect of VAP-1 on an-
giogenesis and metastases in subjects with type 2 diabetes.
Whether there is any tumor-speciﬁc effect of VAP-1 on
tumor surveillance remains to be further investigated.
The strength of this study is in the 100% follow-up rate
after 10 years, with accurate records of the vital status of
a homogenous population of Han Chinese. In addition, the
highly sensitive time-resolved immunoﬂuorometric assay
for measuring serum VAP-1 enabled us to differentiate
subtle differences in circulating VAP-1 concentrations.
However, our study had some limitations. First, serum
VAP-1 was measured only once at baseline, which may
limit the value of serum VAP-1 over time for the prediction
of outcomes. Second, generalization of the ﬁndings to
other populations may be limited because all the subjects
in the current study were Han Chinese. Third, determination
of proteinuria by reﬂectance colorimetry is relatively in-
sensitive and may not accurately detect kidney dysfunction.
In conclusion, we showed for the ﬁrst time that serum
VAP-1 can independently predict 10-year all-cause mor-
tality, cardiovascular mortality, and cancer-related mor-
tality in subjects with type 2 diabetes. Our results showed
that serum VAP-1 is a novel biomarker and improves risk
prediction over and above the established risk factors for
cardiovascular and cancer mortality in subjects with type 2
diabetes. Our data also indicated the potential of using
VAP-1/SSAO inhibitors or antibodies, which are currently
being tested for their ability to treat autoimmune diseases
and to treat or prevent cardiovascular diseases and cancer
in high-risk individuals with type 2 diabetes.
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TABLE 5
The concordance statistics and AUC without indicated variables in models predicting 10-year all-cause mortality for people with type 2
diabetes
Model 1 Model 2 Model 3
Concordance
statistics AUC
Concordance
statistics AUC
Concordance
statistics AUC
Full model 0.64 0.65 (0.60–0.70) 0.73 0.78 (0.73–0.82) 0.78 0.84 (0.79–0.88)
Variable deleted from models
Ln serum VAP-1 (ng/mL) 0.53 (0.11) 0.53 (0.12) 0.71 (0.02) 0.75 (0.03) 0.75 (0.03) 0.82 (0.02)
History of cardiovascular disease 0.63 (0.01) 0.64 (0.01) 0.73 (0) 0.78 (0) 0.78 (0) 0.84 (0)
Age (years) 0.68 (0.05) 0.72 (0.06) 0.76 (0.02) 0.82 (0.02)
Female sex 0.73 (0) 0.78 (0) 0.78 (0) 0.84 (0)
Smoking 0.72 (0.01) 0.76 (0.02) 0.78 (0) 0.83 (0.01)
BMI category (kg/m
2) 0.73 (0) 0.77 (0.01) 0.78 (0) 0.84 (0)
Hypertension 0.73 (0) 0.77 (0.01) 0.78 (0) 0.84 (0)
HbA1c (%) 0.73 (0) 0.77 (0.01) 0.78 (0) 0.84 (0)
Diabetes duration (years) 0.73 (0) 0.77 (0.01) 0.78 (0) 0.84 (0)
Total cholesterol (mg/dL) 0.73 (0) 0.78 (0) 0.78 (0) 0.84 (0)
Statins 0.73 (0) 0.77 (0.01) 0.78 (0) 0.84 (0)
ABI ,0.9 or .1.3 0.73 (0) 0.77 (0.01) 0.78 (0) 0.84 (0)
Estimated GFR
(mL/min per 1.73 m
2) 0.77 (0.01) 0.81 (0.03)
Proteinuria 0.76 (0.02) 0.82 (0.02)
Model 1, Ln serum VAP-1 and history of cardiovascular disease; model 2, Ln serum VAP-1, history of cardiovascular disease, age, sex,
smoking, BMI category, hypertension, HbA1c, diabetes duration, total cholesterol, statins, and ABI; model 3, model 2 plus estimated GFR,
and proteinuria. Differences of concordance statistics or area under the ROC between reduced and full models are shown in parentheses.
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